Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated ...
Eastern Cooperative Oncology Group (ECOG) performance status (PS) is a key clinical variable for cancer treatment and research, but it is usually only recorded in unstructured form in the electronic ...
Adagrasib is effective in older patients with stage IV, KRAS-mutated non-small cell lung cancer, but not in patients with ECOG PS 2.
The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results